A further chance for the UK Supreme Court to consider plausibility?

The Supreme Court has confirmed that Bristol Myers Squibb have recently filed an Application for Permission to Appeal the decision of the Court of Appeal in the Sandoz and Teva v BMS apixaban compound proceedings. As my colleague Aida Tohala reported last month, the UK Court of Appeal decision followed hot on the heels of the EBA's decision in G2/21. For the time being, at least, plausibility remains a hot topic in the UK.